Drug Approval | May 12, 2022
USFDA approves Lilly and Incyte's Olumiant to treat hospitalised patients with Covid-19
Olumiant is the first and only JAK inhibitor USFDA-approved for the treatment of Covid-19
Olumiant is the first and only JAK inhibitor USFDA-approved for the treatment of Covid-19
The funding will enable the company to expand into the segment of HealthCare Service offerings, both in terms of geography and operations
Nirsevimab is the first investigational immunization designed to protect all infants across the RSV season with a single dose
RNA extraction free kit to deliver results in just 45 minutes
The campaign will be available in nine Indian languages namely Hindi, English, Odia, Marathi, Tamil, Telugu, Kannada, Malayalam and Bengali
Omega plans to further strengthen its capabilities, deepen domain expertise and build new solutions
Bora establishes a leadership position in Taiwan's CDMO sector as it continues to expand into the global CDMO market
The plan is to advance innovative therapies to drug-resistant cancers
SCG101 is an autologous T-cell receptor (TCR) T-cell therapy for liver cancer
Under the 5-year exclusive agreement, Artemis DNA will provide Datar's pioneering cancer detection Liquid Biopsies in the USA and Vietnam markets
Subscribe To Our Newsletter & Stay Updated
